AGILeBiotics receives NADP lead development voucher for further development of antibiotics

AGILeBiotics has been awarded a Lead Development Voucher by the Netherlands Antibiotic Development Platform (NADP). The total amount of €50.000 will be allocated to the pre-clinical R&D activities. With this financial support the company will test its antibiotic candidates in a clinically relevant animal model of infection. The next goal is the nomination of an antibiotic candidate for pre-clinical development.

Earlier this year, AGILeBiotics already received an NADP Intellectual Property Voucher. The total amount of €5.000 was allocated to secure AGILeBiotics’ IP position and a patent application was drafted and filed, covering the company’s drug pipeline.

AGILeBiotics BV was launched in March 2017 as a spin-off company of the University of Groningen (RUG). The startup has received an exclusive license from the RUG for the commercial use of a proprietary technology, which gives access to novel antibiotic candidates active against multidrug-resistant infections. Compared to current treatment options, AGILeBiotics’ drug candidates show improved activity against resistant pathogens and broader activity not only against Gram-negative but also Gram-positive bacteria.